hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06373848 id: 346 briefTitle: Comparison of Salivary Parameters in Patients Receiving CoQ10 and Vitamin E Supplementation overallStatus: ENROLLING_BY_INVITATION date: 2024-04-20 date: 2024-08-20 date: 2024-09-15 date: 2024-04-18 date: 2024-04-18 name: Islamic Azad University, Tehran class: OTHER briefSummary: Comparison of salivary markers in patients with Initial chronic periodontitis after non-surgical periodontal treatment with CoQ10 supplementation with vitamin E conditions: Periodontal Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment, Randomized, Double-blind, Controlled design. primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: The study was carried out utilizing a double-blind approach. In order to guarantee objectivity, all three groups - the Vitamin E group, the Coq10 group, and the control group - received medications that were indistinguishable in terms of appearance, packaging, and color. Additionally, to minimize any potential bias, a clinician who had no association with the research labeled the medications as A, B, and C (empty) based on their content, and then distributed them among the patients. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 85 type: ESTIMATED name: Receive 30 mg of Coq10 measure: Total Antioxidant capacity (TAC) of saliva measure: Bleeding on probing sex: ALL minimumAge: 28 Years maximumAge: 35 Years stdAges: ADULT facility: Amirhossein Farahmand city: Tehran zip: 1947833113 country: Iran, Islamic Republic of lat: 35.69439 lon: 51.42151 hasResults: False
nctId: NCT06373835 id: EMODEPSIDE_LAOS briefTitle: Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-07-31 date: 2024-07-31 date: 2024-04-18 date: 2024-04-18 name: Swiss Tropical & Public Health Institute class: OTHER name: National Institute of Public Health, Vientiane, Laos briefSummary: Efficacy, safety and pharmacokinetics of ascending dosages of emodepside and in comparison to ivermectin against Strongyloidiasis stercoralis in adults: randomized stage II seamless adaptive controlled trials conditions: Strongyloides Stercoralis Infection conditions: Strongyloidiasis studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 240 type: ESTIMATED name: Emodepside measure: Cure rate (CR) of emodepside against Strongyloides stercoralis measure: Safety and tolerability of the dose-dependent emodepside treatment regimes, and compared with ivermectin. measure: Geometric Mean Larvae Reduction Rate (LRR) of emodepside against Strongyloides stercoralis. measure: Exposure response of emodepside in adults measure: Cure rate (CR) and egg reduction rate (ERR) with other soil-transmitted helminths (STH) and trematodes sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06373822 id: 2024/18JAN/028 briefTitle: New Perspectives in Adenomyosis Pathogenesis With Epigenetic Analysis and miRNAs acronym: ADENO-MIRNA overallStatus: RECRUITING date: 2024-03-21 date: 2031-09 date: 2031-09 date: 2024-04-18 date: 2024-04-22 name: Université Catholique de Louvain class: OTHER briefSummary: Objectives:
Study Design Blood samples will be collected from healthy subjects and adenomyosis patients and miRNAs will be isolated and analyzed to detect potential differences. conditions: Adenomyosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 50 type: ESTIMATED name: Circulating-mirna measure: Circulating-miRNA as diagnostic biomarkers sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CUSL status: RECRUITING city: Brussel state: Woluwe-Saint-Lambert zip: 1200 country: Belgium name: Emilie Wacheul, MD role: CONTACT phone: 027645246 email: emilie.wacheul@uclouvain.be lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06373809 id: PDSC1970222 briefTitle: Placenta Derived Stem Cells for Treating of Chronic Ulcers and Neuropathy acronym: PDSC overallStatus: COMPLETED date: 2021-10-08 date: 2024-03-31 date: 2024-03-31 date: 2024-04-18 date: 2024-04-18 name: Michael H Carstens class: OTHER name: Ministerio de Salud de Nicaragua name: Wake Forest Institute for Regenerative Medicine briefSummary: This is an initial dose escalation safety and exploratory efficacy study to treat two groups of subjects with critically sized diabetic wounds and diabetic neuropathy using placental-derived stem cells (PDSC) transplanted by injection into soft tissues of the lower limb. Its primary objective is safety assessment and its secondary objective is determining optimum PDSC safe dose. Group 1 will receive implantation of cells in the ulcer, in the ulcer bed, and along the distal arterial vessels that supply blood to the foot. Group 2 will follow the same protocol for the foot but will have an additional dose of cells implanted in the anterior and posterior compartments of the same leg to determine the impact on peripheral neuropathy. Dose escalation and safety will be documented. Exploratory measures of efficacy include: ulcer healing, hemodynamic and anatomical effects on the arteries of the foot, and changes in the sensory perceptions of the foot. conditions: Diabetic Foot conditions: Diabetic Neuropathies conditions: Diabetic Foot Ulcer studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Prospective an open label primaryPurpose: TREATMENT masking: NONE count: 20 type: ACTUAL name: Transplantation of Placenta Derived Stem Cells measure: Foot Ulcer Healing measure: Fine Touch Sensation: Documenting diabetes-associated lower extremity pathophysiology changes. measure: Vibration: Documenting diabetes-associated lower extremity pathophysiology changes. sex: ALL minimumAge: 30 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hospital Escuela Oscar Danilo Rosales Arguello (HEODRA) city: León state: Leon zip: 21000 country: Nicaragua lat: 12.43787 lon: -86.87804 facility: Hospital Escuela Cesar Amador Molina city: Matagalpa zip: 61000 country: Nicaragua lat: 12.92559 lon: -85.91747 hasResults: False
nctId: NCT06373796 id: 2024-A00523-44 briefTitle: Ultrasound Index Fat Fraction acronym: FAT-PLUS overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-07 date: 2024-09 date: 2024-04-18 date: 2024-04-18 name: SuperSonic Imagine class: INDUSTRY briefSummary: The objective is to compare the ultrasound index fat fraction (FAT PLUS), derived from several ultrasound biomarkers, with the gold-standard imaging exam for liver fat content evaluation (MRI-PDFF) in patients to quantify the hepatic steatosis. conditions: Steatosis of Liver studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: Echographic scan measure: FAT PLUS sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373783 id: 2023/05 briefTitle: Ultrasonographic Evaluation of the Connective Tissue Grafts Obtained With Two Different Methods in Root Coverage overallStatus: COMPLETED date: 2023-06-15 date: 2024-01-15 date: 2024-03-16 date: 2024-04-18 date: 2024-04-23 name: Pamukkale University class: OTHER briefSummary: Gingival recession is a clinical problem that increases with age and affects patient comfort. It is defined as the displacement of the gingival margin to a more apical position of the cementum-enamel border of the tooth.
Coronally advanced flap (CAF) or tunnel technique (TUN) with subepithelial connective tissue procedures have been reported to be the most predictable methods of single gingival recession treatments. The ultimate goal of these plastic periodontal surgical procedures is to close the exposed root surface and achieve optimum aesthetic results. The main indications for root coverage (RC) procedures are aesthetic concern, root hypersensitivity, prevention of cervical abrasion and root caries, improvement of restorative results, and facilitation of plaque control. The use of a subepithelial connective tissue graft (SCGT) combined with a coronally positioned flap is considered the gold standard by many authors for single gingival recession treatments.
De-epithelialization of free gingival grafts (DGG) has been proposed, especially when palatal tissue thickness is insufficient (≤2.5 mm) and larger graft size in the apico-coronal or mesio-distal directions is required. In this technique, the graft of the required width and length is separated from the lateral side of the palate, and then the 0.3-0.5 mm thick epithelial layer of the resulting graft is cut from the connective tissue layer.
Ultrasonography (USG) is based on the principle of recording data obtained as a result of ultrasound waves sent with the help of a probe hitting and reflecting on substances of different densities. This technique is widely used in medical practice. In dentistry, the USG method is used to measure the alveolar bone level and the dimensions of the periodontium to evaluate the gingival thickness. It also has functions to evaluate color power and color speed, as well as blood flow.
The study hypothesizes that combining SCGT and DGG with a coronally positioned flap could yield different clinical outcomes in patients with a single buccal gingival recession. This study aims to compare the clinical success of connective tissue grafts obtained by two different surgical methods in covering the root surface with ultrasonography (USG). conditions: Gingival Recession, Localized studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 20 type: ACTUAL name: subepithelial connective tissue graft name: de- epithelize gingival graft name: ultrasonography measure: tissue thickness measure: pulsatility index sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pamukkale University of the Dentistry city: Denizli zip: 20160 country: Turkey lat: 37.77417 lon: 29.0875 hasResults: False
nctId: NCT06373770 id: MSRSW/Batch-Fall22/700 briefTitle: Effects of Ayres Sensory Integration Therapy Versus Conservative Treatment in Autism Spectrum overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-01 date: 2024-06-01 date: 2024-09-30 date: 2024-04-18 date: 2024-04-22 name: Superior University class: OTHER briefSummary: Effects of Ayres Sensory Integration Therapy Versus Conservative Treatment in Autism Spectrum conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 30 type: ACTUAL name: Ayres sensory integration therapy name: Behaviour Therapy measure: sensory profile by winnie dunn sex: ALL minimumAge: 2 Years maximumAge: 8 Years stdAges: CHILD facility: RICCER Institute city: Faisalabad state: Punjab country: Pakistan lat: 31.41554 lon: 73.08969 hasResults: False
nctId: NCT06373757 id: RECO6U/5-2023 briefTitle: Chitosan Nano-hydroxyapatite Hydrogel in Non-Surgical Treatment of Intrabony Defect overallStatus: COMPLETED date: 2023-03-01 date: 2023-09-01 date: 2023-09-01 date: 2024-04-18 date: 2024-04-18 name: October 6 University class: OTHER briefSummary: The aim of this study was to evaluate the clinical effect of Chitosan with nano-hydroxyapatite hydrogel in the treatment of periodontal intrabony defects. conditions: Chitosan conditions: Nano-hydroxyapatite Hydrogel conditions: Intrabony Defect studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 24 type: ACTUAL name: Nano-HAP/Chitosan hydrogel measure: Gingival index measure: Plaque index measure: Clinical attachment level measure: Periodontal probing depth measure: Acrylic stent for pocket assessment sex: ALL minimumAge: 25 Years maximumAge: 55 Years stdAges: ADULT facility: October 6 University city: Giza zip: 12511 country: Egypt lat: 30.00808 lon: 31.21093 hasResults: False
nctId: NCT06373744 id: SYSU-022 briefTitle: Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients overallStatus: COMPLETED date: 2023-01-01 date: 2024-01-01 date: 2024-01-01 date: 2024-04-18 date: 2024-04-18 name: Sun Yat-sen University class: OTHER briefSummary: The goal of this observational study is to learn about the effects of metronomic chemotherapy in advanced breast cancer patients. The main question it aims to answer is:
How effective is metronomic chemotherapy in advanced breast cancer? Specific benefit groups of metronomic chemotherapy. conditions: Breast Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 597 type: ACTUAL name: cyclophosphamide , methotrexate , vinorelbine ,capecitabine measure: Progression free survival measure: Overall Survival measure: Objective Response Rate measure: Disease Control Rate sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shusen Wang city: Guangzhou state: Gangdong country: China lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06373731 id: SPIAM-301 briefTitle: ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD) acronym: ReNEW overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-08 date: 2027-08 date: 2024-04-18 date: 2024-04-22 name: Stealth BioTherapeutics Inc. class: INDUSTRY briefSummary: The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared. conditions: Age-Related Macular Degeneration studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Subjects will be randomized (2:1) to once daily 40 mg SC of elamipretide or placebo for 96 weeks of treatment by a central randomization primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: Trial personnel and subjects will be masked to treatment until the database is locked at the end of the trial, unless noted below. The Investigator will contact the Sponsor Medical Monitor prior to unmasking any subject's treatment sequence unless in the instance of a medical emergency. In case of an immediate medical emergency, or if directed by the Sponsor, and only if the information is required by the Investigator to manage a subject's AE, a subject's treatment assignment may be unmasked prematurely using the computerized system. The Sponsor must be notified as soon as possible regarding the reason for unmasking. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 360 type: ESTIMATED name: Elamipretide name: Placebo measure: Week 48 Rate of change in the macular area of photoreceptor loss measure: Week 72 Rate of change in the Macular area of photoreceptor loss measure: Week 96 Rate of change in the Macular area of photoreceptor loss measure: Proportion of subjects gaining ≥ 10 letters (2 lines) in Low Luminance Best-Corrected Visual Acuity (LL BCVA) measure: Proportion of subjects gaining ≥ 15 letters in Low Luminance Best-Corrected Visual Acuity (LL BCVA) sex: ALL minimumAge: 55 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06373718 id: IRB-74553 briefTitle: A Novel Use of a Sleep Intervention to Target the Emotion Regulation Brain Network to Treat Depression and Anxiety (R33 Phase) overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2027-06 date: 2027-06 date: 2024-04-18 date: 2024-04-18 name: Stanford University class: OTHER name: National Institute of Mental Health (NIMH) briefSummary: This project is the second phase of a two-phased project investigating the impact of a proven sleep intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I) on engagement of the emotion regulation brain network as a putative mechanistic target. conditions: Insomnia conditions: Depression studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Enrolled participants will be randomized into either the Immediate Treatment group, or the Monitored Control group. Both study groups will receive CBT-I. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 150 type: ESTIMATED name: Cognitive Behavioral Therapy for Insomnia measure: Change in Emotion Regulation Network brain activation as assessed by functional magnetic resonance imaging measure: Change in Emotion Regulation Network brain connectivity as assessed by functional magnetic resonance imaging measure: Change in Beck Depression Inventory measure: Change in PSG Sleep Efficiency measure: Change in Columbia Suicide Severity Rating Scale measure: Change in Actigraph Sleep Onset Latency (SOL) as a Measure of Sleep Continuity measure: Change in Actigraph Number of Arousals as a Measure of Sleep Continuity measure: Change in Actigraph Wake After Sleep Onset (WASO) as a Measure of Sleep Continuity measure: Change in Actigraph Total Sleep Time (TST) as a Measure of Sleep Continuity measure: Change in Actigraph Sleep Efficiency (SE) as a Measure of Sleep Continuity measure: Change in PSG Sleep Onset Latency (SOL) as a Measure of Sleep Architecture measure: Change in PSG Number of Arousals as a Measure of Sleep Architecture measure: Change in PSG Wake After Sleep Onset (WASO) as a Measure of Sleep Architecture measure: Change in PSG Total Sleep Time (TST) as a Measure of Sleep Architecture measure: Change in PSG Sleep Efficiency (SE) as a Measure of Sleep Architecture measure: Change in Sleep Physiology measured by PSG measure: Change in Insomnia Severity Index (ISI) Scale Score measure: Change in 36-Item Short Form Survey (SF-36) Score measure: Change in Beck Anxiety Inventory measure: Change in Respiratory Sinus Arrhythmia (RSA)- measured by PSG sex: ALL minimumAge: 25 Years maximumAge: 60 Years stdAges: ADULT facility: Stanford University city: Palo Alto state: California zip: 94304 country: United States name: Pandora Lam role: CONTACT phone: 650-497-5130 email: pal217@stanford.edu name: Andrea Goldstein-Piekarski, PhD role: PRINCIPAL_INVESTIGATOR lat: 37.44188 lon: -122.14302 hasResults: False
nctId: NCT06373705 id: 74566 id: 1R01HL173845 - 01 type: OTHER_GRANT domain: NIH briefTitle: Cardiac Simulator for Surgical Planning overallStatus: NOT_YET_RECRUITING date: 2026-04 date: 2029-04 date: 2029-04 date: 2024-04-18 date: 2024-04-22 name: Stanford University class: OTHER name: National Institutes of Health (NIH) briefSummary: The goal of this clinical trial is to learn if a computer software program (cardiac simulator) for surgical planning will lead to improvements in patient care by decreasing the incidence of unsuccessful interventions and reinterventions for pediatric patients with congenital heart disease. It is not a commercially available device to treat congenital heart disease in pediatric patients. The main aims are:
Receive results of their computer simulated findings during their surgical planning discussion if they are in the cardiac simulator group. conditions: Congenital Heart Disease in Children studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 1:1 randomization to either receive standard of care "on the fly" surgical planning discussion as is current practice or assisted surgical planning discussion with the aid of computer simulation. primaryPurpose: SUPPORTIVE_CARE masking: NONE maskingDescription: After consent to participate in the study, patient will be entered into a random allocation sequence for standard of care (SOC) or cardiac simulator groups.
Patient and surgeon will both be notified which group they have been assigned to. count: 275 type: ESTIMATED name: Cardiac simulator measure: Mortality measure: Mortality measure: Number of cardioplegic arrest measure: Number of repair revisions needed measure: Time on cardiopulmonary bypass measure: Ventricular function measure: Ventricular function measure: Ventricular function measure: Valvular function measure: Valvular function measure: Valvular function measure: Number of days in hospital post-operation measure: Type of post-operative inotrope sex: ALL maximumAge: 17 Years stdAges: CHILD hasResults: False
nctId: NCT06373692 id: TCM for Asthma Cohort briefTitle: REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma) overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-30 date: 2026-12-30 date: 2024-04-18 date: 2024-04-18 name: Henan University of Traditional Chinese Medicine class: OTHER name: The First Affiliated Hospital of Henan University of Traditional Chinese Medicine name: Tianjin University of Traditional Chinese Medicine name: The Third Affiliated Hospital of Henan University of Traditional Chinese Medicine name: Hebei Provincial Hospital of Traditional Chinese Medicine name: Peking University People's Hospital name: The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine name: The First Affiliated Hospital of Zhengzhou University name: First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine name: The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine briefSummary: The purpose of this study is to define the standard use of TCM treatment regimen as the TCM cohort group and the non-TCM cohort group of those who use conventional Western medicine treatment without the standard TCM treatment regimen through a multi-center, large-sample prospective cohort study design. To evaluate the clinical efficacy and safety of TCM treatment regimens in the treatment of bronchial asthma, and to provide high-quality evidence for the promotion and application of TCM syndrome differentiation treatment in bronchial asthma. conditions: Bronchial Asthma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1508 type: ESTIMATED measure: Asthma control rate measure: Number of exacerbations measure: Asthma exacerbation severity measure: Change in severity of chronic persistent disease measure: The dose used by glucocorticoids measure: Rapid-acting beta2 agonists use drugs and doses measure: Asthma Control Test (ACT) score measure: Asthma Control Questionnaire (ACQ) measure: Asthma Quality of Life Score (AQLQ) measure: Anxiety Self-Assessment Form (SAS) measure: Depression Self-Rating Scale (SDS) measure: Pulmonary function measure: Exhaled nitric oxide (FeNO) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Henan University of Traditional Chinese Medicine city: Zhengzhou state: Henan country: China name: Hai-bin Yu, Ph.D role: CONTACT phone: +86 13526671773 email: wwz1231125@163.com lat: 34.75778 lon: 113.64861 hasResults: False